Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC

Clinical Trial The objective of this clinical trial is to determine whether antidepressant medications, such as olanzapine, in combination with immune checkpoint inhibitors are more effective than the use of immune checkpoint inhibitors alone. The main questions it aims to answer are: Is the combination therapy of antidepressant medication with immune checkpoint inhibitors more efficacious than the therapy with immune checkpoint inhibitors alone? What medical issues might participants encounter when treated with the combination of antidepressant medication and immune checkpoint inhibitors?

Trial Details

NCT ID
NCT06554613
Phase
PHASE2
Sponsor
Second Affiliated Hospital of Nanchang University
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Olanzapine
  • Nivolumab
Locations (sample)
  • Nanchang, Jiangxi, China|28.68396,115.85306

Key Eligibility Criteria

  • Participants voluntarily enroll in this study and sign an informed consent form, with good compliance and cooperation with follow-up.
  • Age is over 18 years old (including 18 years old) and under 75 years old (including 75 years old).
  • ECOG score: 0-2 points.
  • Expected survival is no less than 3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →